STOCK TITAN

4D Molecular Therapeutics (FDMT) Revenue by Year

FDMT NASDAQ

4D Molecular Therapeutics, Inc. generated $85.2M in revenue in fiscal year 2025. This represents an increase of 230194.6% from the prior fiscal year. Over the trailing 12 months, Q4 FY2025 through Q3 FY2026, the same line adds up to $96.1M in revenue. The table below carries 7 fiscal years, from 2019 to 2025, and the quarters 4D Molecular Therapeutics, Inc. has filed alongside them.

FY2025 annual
Revenue $85.2M
YoY +230194.6%
5Y CAGR +44.3%
Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

FDMT Revenue by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-K
Revenue$96.1M$85.2M+230194.6%$37K-99.8%$20.7M+562.3%$3.1M-82.7%$18.0M+32.5%$13.6M+94.8%$7.0M

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

FDMT Revenue by Quarter

Figures are in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-K
Revenue$4.1M+4505.6%$3.8M+25106.7%$3.0M+21664.3%$85.1M+8508900.0%$90K+2900.0%$15K+200.0%$14K-50.0%$1K$3K-100.0%$5K-97.9%$28K-90.6%N/A

What revenue means

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it.

More 4D Molecular Therapeutics, Inc. financials

Frequently Asked Questions

4D Molecular Therapeutics, Inc. generated $85.2M in revenue in fiscal year 2025.

4D Molecular Therapeutics, Inc. (FDMT) revenue rose by 230194.6% year over year, from $37K to $85.2M in fiscal year 2025.

4D Molecular Therapeutics, Inc. (FDMT) reported $96.1M in revenue over the trailing 12 months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings.

Across the 7 fiscal years this page covers, 4D Molecular Therapeutics, Inc. (FDMT) revenue went from $7.0M in fiscal year 2019 to $85.2M in fiscal year 2025.

4D Molecular Therapeutics, Inc. (FDMT) reported $4.1M in revenue in Q3 2026. This represents an increase of 4505.6% from the same quarter a year earlier.

Revenue is everything the company billed its customers over the period, counted before any cost of running the business comes out of it. This page lists what 4D Molecular Therapeutics, Inc. (FDMT) reported on that line in every period on record.